Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Pharmacokinetics of BAX 826, a Polysialylated Full-Length rFVIII, in Hemophilia a Mice, Rats, and Cynomolgus Monkeys

Alexandra Schiviz, DVM, Gerald Hoebarth, Martin Wolfsegger, Paolo Rossato, Alfred Weber, Herbert Gritsch, Hanspeter Rottensteiner, PhD, Peter L. Turecek, PhD, Friedrich Scheiflinger, PhD, Werner Hoellriegl, DVM, Marietta Putz, MS

Blood (2015) 126 (23): 1073.

https://doi.org/10.1182/blood.V126.23.1073.1073

Published: 2015

Journal Articles

Non-Proteolytic Regulation of the Multimerization of Von Willebrand Factor By ADAMTS13 Based on a Novel Cysteine Thiol Redundancy

Hanspeter Rottensteiner, PhD, Susanna Skalicky, Birgit Seyfried, PhD, Stefan Kaufmann, Christian Fiedler, Meinhard Hasslacher, PhD, Jing-fei Dong, MD PhD, X. Long Zheng, MD PhD, Barbara Plaimauer, PhD, Friedrich Scheiflinger, PhD

Blood (2015) 126 (23): 2236.

https://doi.org/10.1182/blood.V126.23.2236.2236

Published: 2015

Journal Articles

Temperature-Dependent Irreversible Conformational Change of ADAMTS13 upon Metal Ion Chelation

Rana Grillberger, PhD, Stefan Kaufmann, Barbara Kink, Peter Matthiessen, PhD, Barbara Plaimauer, PhD, Friedrich Scheiflinger, PhD, Hanspeter Rottensteiner, PhD

Blood (2015) 126 (23): 2238.

https://doi.org/10.1182/blood.V126.23.2238.2238

Published: 2015

Journal Articles

Development of BAX 826, a Polysialylated Full-Length rFVIII with Significantly Improved PK Properties

Peter L. Turecek, PhD, Juergen Siekmann, PhD, Artur Mitterer, PhD, Michael Graninger, PhD, Gerald Schrenk, PhD, Peter Matthiessen, PhD, Hanspeter Rottensteiner, PhD, Werner Hoellriegl, DVM, Marietta Putz, MS, Hans Peter Schwarz, MD, Friedrich Scheiflinger, PhD

Blood (2015) 126 (23): 3536.

https://doi.org/10.1182/blood.V126.23.3536.3536

Published: 2015

Journal Articles

Low ADAMTS13 Activity Is a Strong Risk Factor for Ischemic Stroke: A Prospective Cohort Study - the Rotterdam Study

Michelle Alida Helena Sonneveld, MD, Moniek de Maat, PhD, Marileen L.P. Portegies, MD, Albert Hofman, MD PhD, Peter L Turecek, PhD, Hanspeter Rottensteiner, PhD, Friedrich Scheiflinger, PhD, Peter J. Koudstaal, MD PhD, Mohammed A. Ikram, MD PhD, Frank Leebeek, MD PhD

Blood (2014) 124 (21): 113.

https://doi.org/10.1182/blood.V124.21.113.113

Published: 2014

Journal Articles

Importance of Measuring Circulating ADAMTS13 Immune Complexes in Addition to Free Antibodies in Patients with Acquired TTP

Silvia Ferrari, PhD, Barbara Plaimauer, PhD, Bernadette Gruber, Kristina Palavra, Peter L Turecek, PhD, Hartmut J. Ehrlich, MD, Hanspeter Rottensteiner, PhD, Friedrich Scheiflinger, PhD

Blood (2012) 120 (21): 102.

https://doi.org/10.1182/blood.V120.21.102.102

Published: 2012

Journal Articles

Crystal Structure of a Proteolytic Fragment of ADAMTS13 Reveals Alternative Disulfide Pairings in the Cysteine-Rich Domain

Christopher G. Skipwith, BS, Steven Stayrook, PhD, Hanspeter Rottensteiner, PhD, Friedrich Scheiflinger, PhD, X. Long Zheng, MD, PhD

Blood (2012) 120 (21): 3363.

https://doi.org/10.1182/blood.V120.21.3363.3363

Published: 2012

Journal Articles

Preclinical Efficacy Testing of Baxter's Recombinant ADAMTS13 in a Mouse Model of TTP.

Alexandra Schiviz, DVM, Marlene Resch, DVM, Elisa Farnleitner, Hanspeter Rottensteiner, PhD, Friedrich Scheiflinger, PhD, Hans Peter Schwarz, MD, Werner Hoellriegl, PhD, Eva-Maria Muchitsch, DVM

Blood (2012) 120 (21): 2216.

https://doi.org/10.1182/blood.V120.21.2216.2216

Published: 2012

Journal Articles

Impact of Factor IXa Content On Function, Safety and Efficacy of Recombinant Factor IX Products.

Wilfried Auer, PhD, Hanspeter Rottensteiner, PhD, Gerald Schrenk, PhD, Werner Hoellriegl, PhD, Alexandra Schiviz, DVM, Friedrich Scheiflinger, PhD, Hans Peter Schwarz, MD, Peter L Turecek, PhD, Eva-Maria Muchitsch, PhD

Blood (2012) 120 (21): 2233.

https://doi.org/10.1182/blood.V120.21.2233.2233

Published: 2012

Journal Articles

Functional Characterization of Baxter's Recombinant Human ADAMTS13 Drug Candidate.

Hanspeter Rottensteiner, PhD, Barbara Plaimauer, PhD, Gerald Schrenk, PhD, Michaela Schmidt, Bernadette Gruber, Jutta Schreiner, Peter L Turecek, PhD, Friedrich Scheiflinger, PhD

Blood (2012) 120 (21): 2235.

https://doi.org/10.1182/blood.V120.21.2235.2235

Published: 2012

Journal Articles

Structural Characterization of Baxter's Recombinant Human ADAMTS13 Drug Candidate.

Alexandra Foettinger-Vacha, Martin Kaliwoda, PhD, Peter Matthiessen, PhD, Meinhard Hasslacher, PhD, Hanspeter Rottensteiner, PhD, Peter L Turecek, PhD, Artur Mitterer, PhD, Friedrich Scheiflinger, PhD

Blood (2012) 120 (21): 2236.

https://doi.org/10.1182/blood.V120.21.2236.2236

Published: 2012

Journal Articles

In Vivo Cleavage of Recombinant VWF Upon Intravenous Administration in Preclinical and Clinical Settings

Katalin Varadi, PhD, Hanspeter Rottensteiner, PhD, Jutta Schreiner, Herbert Gritsch, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD, Peter L Turecek, PhD

Blood (2011) 118 (21): 1222.

https://doi.org/10.1182/blood.V118.21.1222.1222

Published: 2011

Journal Articles

Absorption, Metabolism, Distribution, and Excretion of Longer Acting rFVIII (BAX 855) Following Intravenous Administration to Rats

Reinhard Stidl, PhD, Juergen Siekmann, PhD, Sean M Culbertson, Tony Vinson, Antoni Kozlowski, Xiaoming Shen, Mary J Bossard, Hanspeter Rottensteiner, PhD, Barbara Dietrich, DVM, Chyung Cook, Peter L Turecek, PhD, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD, Hans Peter Schwarz, MD, Eva-Maria Muchitsch

Blood (2011) 118 (21): 4358.

https://doi.org/10.1182/blood.V118.21.4358.4358

Published: 2011

Journal Articles

Functional Characterization of BAX 855, a PEGylated Recombinant FVIII

Gerald Schrenk, PhD, Katalin Varadi, PhD, Herbert Gritsch, Hanspeter Rottensteiner, PhD, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD, Peter L Turecek, PhD

Blood (2011) 118 (21): 4359.

https://doi.org/10.1182/blood.V118.21.4359.4359

Published: 2011

Journal Articles

2D-DIGE As a Tool to Analyze Lot-to-Lot Consistency of Complex Therapeutic Products Such As BAX 855, a PEGylated Recombinant FVIII

Hanspeter Rottensteiner, PhD, Christina Monetti, Herbert Gritsch, Alfred Weber, PhD, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD, Peter L Turecek, PhD

Blood (2011) 118 (21): 4360.

https://doi.org/10.1182/blood.V118.21.4360.4360

Published: 2011

Journal Articles

Detection of Circulating ADAMTS13 Immune Complexes by Antibody Class-Specific ELISA

Barbara Plaimauer, PhD, Silvia Ferrari, Bernadette Gruber, Hanspeter Rottensteiner, PhD, Peter L Turecek, PhD, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD

Blood (2011) 118 (21): 4361.

https://doi.org/10.1182/blood.V118.21.4361.4361

Published: 2011

Journal Articles

Development of a Large Scale Production Process for BAX 855, a PEGylated rFVIII Product with Prolonged Half-Life

Jürgen Siekmann, PhD, Purtscher Martin, PhD, Oliver Zöchling, Robert Kellerer, Hanspeter Rottensteiner, PhD, Artur Mitterer, PhD, Marry Bossard, PhD, Gayle Phillips, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD, Peter L Turecek, PhD

Blood (2011) 118 (21): 4362.

https://doi.org/10.1182/blood.V118.21.4362.4362

Published: 2011

Journal Articles

Development and Validation of a Predictive Model for Death in Acquired Severe ADAMTS13 Deficiency-Associated Idiopathic Thrombotic Thrombocytopenic Purpura: The French TMA Reference Center Experience

Ygal Benhamou, Cyrielle Assie, Pierre-Yves Boelle, Marc Buffer, Rana Grillberger, PharmD, Sandrine Malot, Dominique Bordessoule, Lionel Galicier, MD, Elie Azoulay, MD, PhD, Hanspeter Rottensteiner, PhD, Agnes Veyradier, Paul Coppo

Blood (2011) 118 (21): 2229.

https://doi.org/10.1182/blood.V118.21.2229.2229

Published: 2011

Journal Articles

Binding of FVIII to Recombinant VWF

Gerald Schrenk, PhD, Katalin Varadi, PhD, Hanspeter Rottensteiner, PhD, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD, Peter Turecek, PhD

Blood (2010) 116 (21): 1408.

https://doi.org/10.1182/blood.V116.21.1408.1408

Published: 2010

Journal Articles

Investigation of the Morphology of Recombinant Von Willebrand Factor by Two High-Resolution Microscopic Techniques

Hanspeter Rottensteiner, PhD, Birgit K Seyfried, PhD, Gernot Friedbacher, PhD, Guenter Allmaier, PhD, Nicola Ilk, PhD, Uwe B Sleytr, PhD, Hartmut J. Ehrlich, MD, Peter L Turecek, PhD

Blood (2010) 116 (21): 1409.

https://doi.org/10.1182/blood.V116.21.1409.1409

Published: 2010

NARROW

Pharmacokinetics of BAX 826, a Polysialylated Full-Length rFVIII, in Hemophilia a Mice, Rats, and Cynomolgus Monkeys

Non-Proteolytic Regulation of the Multimerization of Von Willebrand Factor By ADAMTS13 Based on a Novel Cysteine Thiol Redundancy

Temperature-Dependent Irreversible Conformational Change of ADAMTS13 upon Metal Ion Chelation

Development of BAX 826, a Polysialylated Full-Length rFVIII with Significantly Improved PK Properties

Low ADAMTS13 Activity Is a Strong Risk Factor for Ischemic Stroke: A Prospective Cohort Study - the Rotterdam Study

Importance of Measuring Circulating ADAMTS13 Immune Complexes in Addition to Free Antibodies in Patients with Acquired TTP

Crystal Structure of a Proteolytic Fragment of ADAMTS13 Reveals Alternative Disulfide Pairings in the Cysteine-Rich Domain

Preclinical Efficacy Testing of Baxter's Recombinant ADAMTS13 in a Mouse Model of TTP.

Impact of Factor IXa Content On Function, Safety and Efficacy of Recombinant Factor IX Products.

Functional Characterization of Baxter's Recombinant Human ADAMTS13 Drug Candidate.

Structural Characterization of Baxter's Recombinant Human ADAMTS13 Drug Candidate.

In Vivo Cleavage of Recombinant VWF Upon Intravenous Administration in Preclinical and Clinical Settings

Absorption, Metabolism, Distribution, and Excretion of Longer Acting rFVIII (BAX 855) Following Intravenous Administration to Rats

Functional Characterization of BAX 855, a PEGylated Recombinant FVIII

2D-DIGE As a Tool to Analyze Lot-to-Lot Consistency of Complex Therapeutic Products Such As BAX 855, a PEGylated Recombinant FVIII

Detection of Circulating ADAMTS13 Immune Complexes by Antibody Class-Specific ELISA

Development of a Large Scale Production Process for BAX 855, a PEGylated rFVIII Product with Prolonged Half-Life

Development and Validation of a Predictive Model for Death in Acquired Severe ADAMTS13 Deficiency-Associated Idiopathic Thrombotic Thrombocytopenic Purpura: The French TMA Reference Center Experience

Binding of FVIII to Recombinant VWF

Investigation of the Morphology of Recombinant Von Willebrand Factor by Two High-Resolution Microscopic Techniques

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only